Vicapsys Life Sciences, Inc. (VICP) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US92560A1060
Vicapsys Life Sciences, Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Operating income | -813,836.00 USD | -651,803.00 USD |
| Net income | -989,798.00 USD | -689,887.00 USD |
Full history since 2008, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Vicapsys Life Sciences, Inc.
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.
More stocks
- Context Therapeutics Inc. (CNTX)
- REGIONAL HEALTH PROPERTIES, INC (RHEPB)
- Teads Holding Co. (TEAD)
- Cosmos Health Inc. (COSM)
- ARK RESTAURANTS CORP (ARKR)
- Beam Global (BEEM)
- AmBase Corp (ABCP)
- Sphere 3D Corp. (ANY)
- MERCER INTERNATIONAL INC. (MERC)
- Beeline Holdings, Inc. (BLNE)
- Sentinel Holdings Ltd. (SNTL)
- Vivid Seats Inc. (SEAT)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.